LIVIVO - Search results -

Search results

Result 1 - 10 of total 19

Search options

Article: Foam Cells in Atherosclerosis: Novel Insights Into Its Origins, Consequences, and Molecular Mechanisms.

Gui, Yuzhou / Zheng, Hongchao / Cao, Richard Y

2022 Volume 9, Page(s) 845942

Abstract: Foam cells play a vital role in the initiation and development of atherosclerosis. This review aims to summarize the novel insights into the origins, consequences, and molecular mechanisms of foam cells in atherosclerotic plaques. Foam cells are ... ...

Abstract	Foam cells play a vital role in the initiation and development of atherosclerosis. This review aims to summarize the novel insights into the origins, consequences, and molecular mechanisms of foam cells in atherosclerotic plaques. Foam cells are originated from monocytes as well as from vascular smooth muscle cells (VSMC), stem/progenitor cells, and endothelium cells. Novel technologies including lineage tracing and single-cell RNA sequencing (scRNA-seq) have revolutionized our understanding of subtypes of monocyte- and VSMC-derived foam cells. By using scRNA-seq, three main clusters including resident-like, inflammatory, and triggering receptor expressed on myeloid cells-2 (Trem2
Language	English
Publishing date	2022-04-13
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2022.845942
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist.

Liu, Yun / Wang, Wei / Qian, Hongjie / Gui, Yuzhou / Wang, Yating / Song, Rong / Chen, Qian / Rowinsky, Eric / Wang, Sheng / Liang, Xiaoguang / Gu, Kaicun / Zhou, Bo / Zhang, Weiwei / Zhang, Liqin / Yu, Chen / Jia, Jingying

Clinical and translational science

2024 Volume 17, Issue 3, Page(s) e13750

Abstract: This study evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and food effects (FE) of SC0062, a highly active endothelin-A ( ... ...

Abstract	This study evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and food effects (FE) of SC0062, a highly active endothelin-A (ET
MeSH term(s)	Humans ; Asian People ; Bile Acids and Salts ; China ; Fasting ; Healthy Volunteers
Chemical Substances	Bile Acids and Salts
Language	English
Publishing date	2024-03-07
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2433157-0
ISSN	1752-8062 ; 1752-8054
ISSN (online)	1752-8062
ISSN	1752-8054
DOI	10.1111/cts.13750
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Development and validation of a ligand-binding assay for quantification of the F(ab')

Gui, Yuzhou / Yu, Chengyin / Zhou, Jiaye / Xin, Liang / Chen, Ze / Fan, Tiejiong / Lu, Shuang / Jia, Jingying / Liu, Gangyi

Journal of pharmaceutical and biomedical analysis

2022 Volume 212, Page(s) 114645

Abstract: Daboia russelii siamensis accounts for most of snakebite mortalities in China, yet, specific treatment against the venom toxins is absent in clinical practice. The F(ab') ...

Abstract	Daboia russelii siamensis accounts for most of snakebite mortalities in China, yet, specific treatment against the venom toxins is absent in clinical practice. The F(ab')
MeSH term(s)	Animals ; Antivenins/therapeutic use ; Humans ; Ligands ; Daboia ; Snake Bites/drug therapy ; Viper Venoms/therapeutic use
Chemical Substances	Antivenins ; Ligands ; Viper Venoms
Language	English
Publishing date	2022-02-04
Publishing country	England
Document type	Clinical Trial, Phase I ; Journal Article
ZDB-ID	604917-5
ISSN	1873-264X ; 0731-7085
ISSN (online)	1873-264X
ISSN	0731-7085
DOI	10.1016/j.jpba.2022.114645
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1850: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects.

Qian, Hongjie / Cheng, Jie / Gui, Yuzhou / Wang, Wei / Liang, Liyu / Zhu, Huijuan / Wu, Qingqing / Ou, Meixian / Chen, Qian / Yu, Chen / Jia, Jingying

Clinical and translational science

2023 Volume 16, Issue 9, Page(s) 1704–1712

Abstract: This study aimed to evaluate the pharmacokinetic (PK) similarity of the proposed biosimilar HS628 compared with the reference tocilizumab (Actemra®) and also to demonstrate similar safety and immunogenicity profiles in healthy Chinese male subjects. ... ...

Abstract	This study aimed to evaluate the pharmacokinetic (PK) similarity of the proposed biosimilar HS628 compared with the reference tocilizumab (Actemra®) and also to demonstrate similar safety and immunogenicity profiles in healthy Chinese male subjects. Eighty eligible subjects were randomized into two treatment groups in a 1:1 ratio to receive a single intravenous infusion of HS628 or tocilizumab at 4 mg/kg over 60 min. Blood samples were collected at the scheduled time points for PK and immunogenicity analysis. PK biosimilarity was determined using the standard bioequivalence criteria 80%-125%. A total of 77 subjects received the study drug and completed the study. The main PK parameters were similar for the test and reference groups. The ratio of geometric least-squares means (GMR) and its 90% CIs for AUC
MeSH term(s)	Humans ; Male ; Biosimilar Pharmaceuticals ; Antibodies, Monoclonal, Humanized/adverse effects ; Therapeutic Equivalency ; Area Under Curve ; Healthy Volunteers ; Double-Blind Method
Chemical Substances	tocilizumab (I031V2H011) ; Biosimilar Pharmaceuticals ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2023-07-18
Publishing country	United States
Document type	Randomized Controlled Trial ; Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2433157-0
ISSN	1752-8062 ; 1752-8054
ISSN (online)	1752-8062
ISSN	1752-8054
DOI	10.1111/cts.13584
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Direct analysis in real time-mass spectrometry for rapid quantification of five anti-arrhythmic drugs in human serum: application to therapeutic drug monitoring.

Gui, Yuzhou / Lu, Youli / Li, Shuijun / Zhang, Mengqi / Duan, Xiaokun / Liu, Charles C / Jia, Jingying / Liu, Gangyi

Scientific reports

2020 Volume 10, Issue 1, Page(s) 15550

Abstract: Therapeutic drug monitoring (TDM) is necessary for the optimal administration of anti-arrhythmic drugs in the treatment of heart arrhythmia. The present study aimed to develop and validate a direct analysis in real time tandem mass spectrometry (DART-MS/ ... ...

Abstract	Therapeutic drug monitoring (TDM) is necessary for the optimal administration of anti-arrhythmic drugs in the treatment of heart arrhythmia. The present study aimed to develop and validate a direct analysis in real time tandem mass spectrometry (DART-MS/MS) method for the rapid and simultaneous determination of five anti-arrhythmic drugs (metoprolol, diltiazem, amiodarone, propafenone, and verapamil) and one metabolite (5-hydroxy(OH)-propafenone) in human serum. After the addition of isotope-labeled internal standards and protein precipitation with acetonitrile, anti-arrhythmic drugs were ionized by DART in positive mode followed by multiple reaction monitoring (MRM) detection. The use of DART-MS/MS avoided the need for chromatographic separation and allowed rapid and ultrahigh throughput analysis of anti-arrhythmic drugs in a total run time of 30 s per sample. The DART-MS/MS method yielded satisfactory linearity (R
MeSH term(s)	Amiodarone/blood ; Anti-Arrhythmia Agents/blood ; Anti-Arrhythmia Agents/therapeutic use ; Chromatography, High Pressure Liquid ; Computer Systems ; Diltiazem/blood ; Drug Monitoring/methods ; Humans ; Metoprolol/blood ; Pharmaceutical Preparations ; Propafenone/blood ; Tandem Mass Spectrometry ; Verapamil/blood
Chemical Substances	Anti-Arrhythmia Agents ; Pharmaceutical Preparations ; Propafenone (68IQX3T69U) ; Verapamil (CJ0O37KU29) ; Diltiazem (EE92BBP03H) ; Metoprolol (GEB06NHM23) ; Amiodarone (N3RQ532IUT)
Language	English
Publishing date	2020-09-23
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-020-72490-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).

EClinicalMedicine

2023 Volume 67, Page(s) 102372

Abstract: Background: The mRNA vaccine has demonstrated significant effectiveness in protecting against SARS-CoV-2 during the pandemic, including against severe forms of the disease caused by emerging variants. In this study, we examined safety, immunogenicity, ... ...

Abstract	Background: The mRNA vaccine has demonstrated significant effectiveness in protecting against SARS-CoV-2 during the pandemic, including against severe forms of the disease caused by emerging variants. In this study, we examined safety, immunogenicity, and relative efficacy of a heterologous booster of the lipopolyplex (LPP)-based mRNA vaccine (SW-BIC-213) versus a homologous booster of an inactivated vaccine (BBIBP) in Laos. Methods: In this phase 3 clinical trial, which was randomized, parallel controlled and double-blinded, healthy adults aged 18 years and above were recruited from the Southern Savannakhet Provincial Hospital and Champhone District Hospital. The primary outcomes were safety and immunogenicity, with efficacy as an exploratory endpoint. Participants who were fully immunized with a two-dose inactivated vaccine for more than 6 months were assigned equally to either the SW-BIC-213 group (25 μg) or BBIBP group. The primary safety endpoint was to describe the safety profile of all participants in each group up to 6 months post-booster immunization. The primary immunogenic outcome was to demonstrate the superiority of the neutralizing antibody response, in terms of geometric mean titers (GMTs) of SW-BIC-213, compared with BBIBP 28 days after the booster dose. The exploratory efficacy endpoint aimed to assess the relative efficacy of SW-BIC-213 compared to BBIBP against virologically confirmed symptomatic COVID-19 over a 6-month period. The trial was registered with ClinicalTrials.gov (NCT05580159). Findings: Between October 10, 2022, and January 13, 2023, 1200 participants were assigned to SW-BIC-213 group and 1203 participants in the BBIBP group. All adverse reactions observed during the study were tolerable, transient, and resolved spontaneously. Solicited local reactions were the main adverse reactions in both the SW-BIC-213 group (43.8%) and BBIBP group (14.8%) (p < 0.001). Heterologous boosting with SW-BIC-213 induced higher live virus neutralizing antibodies to SARS-CoV-2 wildtype and BA.5 strains with GMTs reaching 750.1 and 192.9 than homologous boosting with BBIBP with GMTs of 131.5 (p < 0.001) and 47.5 (p < 0.001) on day 29. The statistical findings revealed that, following a period of 14-day to 6-month after booster vaccination, the SW-BIC-213 group exhibited a relative vaccine efficacy (VE) of 70.1% (95% CI: 34.2-86.4) against symptomatic COVID-19 when compared to the BBIBP group. Interpretation: A heterologous booster with the COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and proves highly immunogenic and efficacious in preventing symptomatic COVID-19 in individuals who have previously received two doses of inactivated vaccine. Funding: Shanghai Strategic Emerging Industries Development Special Fund, Biomedical Technology Support Special Project of Shanghai "Science and Technology Innovation Action Plan", Shanghai Municipal Science and Technology Commission.
Language	English
Publishing date	2023-12-13
Publishing country	England
Document type	Journal Article
ISSN	2589-5370
ISSN (online)	2589-5370
DOI	10.1016/j.eclinm.2023.102372
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial.

Gui, Yu-Zhou / Li, Xue-Ning / Li, Jing-Xin / Shen, Ming-Yun / Zhang, Mei-Wei / Cao, Ye / Xu, Hong-Rong / Li, Hui / Cheng, Jie / Pan, Liang / Yi, Ying-Lei / Liang, Li-Yu / Yu, Cheng-Yin / Liu, Gang-Yi / Yu, Chen / Hu, Bi-Jie / Zhu, Feng-Cai / Liang, Fei / Shen, Haifa /

Jia, Jing-Ying / Li, Hang-Wen / Zhou, Jian / Fan, Jia

EBioMedicine

2023 Volume 91, Page(s) 104586

Abstract: Background: We assessed the safety and immunogenicity of a core-shell structured lipopolyplex (LPP) based COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults.: Methods: We conducted an open-labeled, two-centered, and three- ... ...

Abstract	Background: We assessed the safety and immunogenicity of a core-shell structured lipopolyplex (LPP) based COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults. Methods: We conducted an open-labeled, two-centered, and three-arm randomised phase 1 trial. Healthy adults, who had completed a two-dose of inactivated COVID-19 vaccine for more than six months, were enrolled and randomized to receive a booster dose of COVILO (inactivated vaccine) (n = 20) or SW-BIC-213-25μg (n = 20), or SW-BIC-213-45μg (n = 20). The primary study endpoint was adverse events within 30 days post-boosting. The secondary endpoint was the titers of binding antibodies and neutralizing antibodies against the wild-type (WT) of SARS-CoV-2 as well as variants of concern in serum. The exploratory endpoint was the cellular immune responses. This trial was registered with http://www.chictr.org.cn (ChiCTR2200060355). Findings: Between Jun 6 and Jun 22, 2022, 60 participants were enrolled and randomized to receive a booster dose of SW-BIC-213 (25 μg, n = 20, or 45 μg, n = 20) or COVILO (n = 20). The baseline demographic characteristics of the participants at enrollment were similar among the treatment groups. For the primary outcome, injection site pain and fever were more common in the SW-BIC-213 groups (25 μg and 45 μg). Grade 3 fever was reported in 25% (5/20) of participants in the SW-BIC-213-45μg group but was resolved within 48 h after onset. No fatal events or adverse events leading to study discontinuation were observed. For secondary and exploratory outcomes, SW-BIC-213 elicited higher and longer humoral and cellular immune responses than that in the COVILO group. Interpretation: SW-BIC-213, a core-shell structured lipopolyplex (LPP) based mRNA vaccine, was safe, tolerable, and immunogenic as a heterologous booster in healthy Chinese adults. Funding: Shanghai Municipal Government, the Science and Technology and Economic Commission of Shanghai Pudong New Area, and mRNA Innovation and Translation Center of Shanghai.
MeSH term(s)	Adult ; Humans ; COVID-19 Vaccines/adverse effects ; COVID-19/prevention & control ; SARS-CoV-2 ; Antibodies, Viral ; China ; Antibodies, Neutralizing ; Double-Blind Method ; mRNA Vaccines
Chemical Substances	BIBP COVID-19 vaccine ; COVID-19 Vaccines ; Antibodies, Viral ; Antibodies, Neutralizing
Language	English
Publishing date	2023-04-24
Publishing country	Netherlands
Document type	Randomized Controlled Trial ; Clinical Trial, Phase I ; Journal Article
ZDB-ID	2851331-9
ISSN	2352-3964
ISSN (online)	2352-3964
DOI	10.1016/j.ebiom.2023.104586
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7090: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Betulin attenuates atherosclerosis in apoE

Gui, Yu-Zhou / Yan, Hong / Gao, Fei / Xi, Cong / Li, Hui-Hui / Wang, Yi-Ping

Acta pharmacologica Sinica

2016 Volume 37, Issue 10, Page(s) 1337–1348

Abstract: Aim: Betulin is a pentacyclic triterpenoid isolated from the bark of yellow and white birch trees with anti-cancer and anti-malaria activities. In this study we examined the effects of betulin on atherosclerosis in apoE: Methods: Murine macrophage ... ...

Abstract	Aim: Betulin is a pentacyclic triterpenoid isolated from the bark of yellow and white birch trees with anti-cancer and anti-malaria activities. In this study we examined the effects of betulin on atherosclerosis in apoE Methods: Murine macrophage RAW264.7 cells and human monocyte-derived THP-1 cells were tested. Foam cell formation was detected with Oil Red O staining. Cholesterol efflux was assessed using [ Results: In RAW264.7 cells, betulin (0.1-2.5 μg/mL) dose-dependently ameliorated oxLDL-induced cholesterol accumulation and enhanced cholesterol efflux. In both RAW264.7 and THP-1 cells, betulin increased the expression of ABCA1 and ABCG1 via suppressing the transcriptional repressors sterol-responsive element-binding proteins (SREBPs) that bound to E-box motifs in ABCA1 promoter, whereas E-box binding site mutation markedly attenuated betulin-induced ABCA1 promoter activity. In HFD-fed apoE Conclusion: Betulin attenuates atherosclerosis in apoE
MeSH term(s)	ATP Binding Cassette Transporter 1/metabolism ; ATP Binding Cassette Transporter, Sub-Family G, Member 1/metabolism ; Animals ; Anticholesteremic Agents/pharmacology ; Anticholesteremic Agents/therapeutic use ; Apolipoproteins E/genetics ; Atherosclerosis/drug therapy ; Atherosclerosis/metabolism ; Cell Line ; Cholesterol/metabolism ; Humans ; Macrophages/metabolism ; Male ; Mice ; Sterol Regulatory Element Binding Proteins/antagonists & inhibitors ; Triterpenes/pharmacology ; Triterpenes/therapeutic use ; Up-Regulation
Chemical Substances	ABCA1 protein, mouse ; ABCG1 protein, mouse ; ATP Binding Cassette Transporter 1 ; ATP Binding Cassette Transporter, Sub-Family G, Member 1 ; Anticholesteremic Agents ; Apolipoproteins E ; Sterol Regulatory Element Binding Proteins ; Triterpenes ; betulin (6W70HN7X7O) ; Cholesterol (97C5T2UQ7J)
Language	English
Publishing date	2016-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	1360774-1
ISSN	1745-7254 ; 0253-9756 ; 1671-4083
ISSN (online)	1745-7254
ISSN	0253-9756 ; 1671-4083
DOI	10.1038/aps.2016.46
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1904: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma.

Zhang, Mengqi / Liu, Haiming / He, Jiajin / Gui, Yuzhou / Qian, Hongjie / Jia, Jingying / Yu, Chen / Wang, Zhen / Shen, Jing Shan / Liu, Gangyi

Journal of pharmaceutical and biomedical analysis

2020 Volume 191, Page(s) 113634

Abstract: A simple, rapid and accurate method for quantitative analysis of a highly selective phosphodiesterase-5 inhibitor (PDE5), TPN171 by high performance liquid chromatography and tandem mass spectrometry in human plasma was proposed and validated ... ...

Abstract	A simple, rapid and accurate method for quantitative analysis of a highly selective phosphodiesterase-5 inhibitor (PDE5), TPN171 by high performance liquid chromatography and tandem mass spectrometry in human plasma was proposed and validated successfully using D
MeSH term(s)	Chromatography, High Pressure Liquid ; Chromatography, Liquid ; Humans ; Pyrimidinones ; Reproducibility of Results ; Sensitivity and Specificity ; Spectrometry, Mass, Electrospray Ionization ; Tandem Mass Spectrometry
Chemical Substances	Pyrimidinones ; TPN171
Language	English
Publishing date	2020-09-17
Publishing country	England
Document type	Journal Article
ZDB-ID	604917-5
ISSN	1873-264X ; 0731-7085
ISSN (online)	1873-264X
ISSN	0731-7085
DOI	10.1016/j.jpba.2020.113634
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1850: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.

Gui, Yuzhou / Yao, Sheng / Yan, Hong / Hu, Liang / Yu, Chengyin / Gao, Fei / Xi, Cong / Li, Huihui / Ye, Yang / Wang, Yiping

Cardiovascular research

2016 Volume 112, Issue 1, Page(s) 502–514

Abstract: Aims: Atherosclerosis is the most common cause of cardiovascular diseases, such as myocardial infarction and stroke. We hypothesized that nagilactone B (NLB), a small molecule extracted from the root bark of Podocarpus nagi (Podocarpaceae), suppresses ... ...

Abstract	Aims: Atherosclerosis is the most common cause of cardiovascular diseases, such as myocardial infarction and stroke. We hypothesized that nagilactone B (NLB), a small molecule extracted from the root bark of Podocarpus nagi (Podocarpaceae), suppresses atherosclerosis in an atherosclerotic mouse model. Methods and results: Male apoE-deficient mice on C57BL/6J background received NLB (10 and 30 mg/kg) for 12 weeks. Compared with the model group, NLB treatment (10 and 30 mg/kg) significantly reduced en face lesions of total aorta areas. In RAW264.7 cells, NLB significantly ameliorated cholesterol accumulation in macrophages via enhancing apolipoprotein A-I and HDL-mediated cholesterol efflux. Mechanistically, NLB induced messenger RNA and protein expression of the ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in RAW264.7 and THP-1 cells. Liver X receptor (LXR) site mutations in the mouse ABCA1 promoter abrogated NLB-mediated luciferase reporter activity. LXRα and LXRβ small interfering RNA suppressed NLB-mediated induction of ABCA1 expression. Consistent with in vitro results, NLB induced ABCA1 expression and suppressed macrophage areas in the aortic sinus. Moreover, NLB treatment did not induce the protein expression of LXR in liver. Hepatic and intestinal cholesterol accumulation was significantly alleviated on NLB treatment. Besides, NLB significantly improved plasma lipid profiles in apoE-deficient mice. Conclusion: Selective LXR activation in macrophages with NLB induces ABCA1- and ABCG1-mediated cholesterol efflux while exerting minimal effects on lipogenesis and lipid accumulation in liver, resulting in regression of atherosclerosis, and therefore might be a promising strategy for therapeutics.
MeSH term(s)	ATP Binding Cassette Transporter 1/genetics ; ATP Binding Cassette Transporter 1/metabolism ; ATP Binding Cassette Transporter, Sub-Family G, Member 1/genetics ; ATP Binding Cassette Transporter, Sub-Family G, Member 1/metabolism ; Animals ; Aorta/drug effects ; Aorta/metabolism ; Aorta/pathology ; Aortic Diseases/genetics ; Aortic Diseases/metabolism ; Aortic Diseases/pathology ; Aortic Diseases/prevention & control ; Apolipoprotein A-I/metabolism ; Apolipoproteins E/deficiency ; Apolipoproteins E/genetics ; Atherosclerosis/genetics ; Atherosclerosis/metabolism ; Atherosclerosis/pathology ; Atherosclerosis/prevention & control ; Binding Sites ; Cell Line, Tumor ; Cholesterol, HDL/metabolism ; Disease Models, Animal ; Diterpenes/pharmacology ; Dose-Response Relationship, Drug ; Genetic Predisposition to Disease ; Humans ; Hypolipidemic Agents/pharmacology ; Liver X Receptors/agonists ; Liver X Receptors/drug effects ; Liver X Receptors/genetics ; Macrophages/drug effects ; Macrophages/metabolism ; Macrophages/pathology ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Mutation ; Phenotype ; Plaque, Atherosclerotic ; Promoter Regions, Genetic ; RAW 264.7 Cells ; RNA Interference ; Signal Transduction/drug effects ; Transfection
Chemical Substances	ABCA1 protein, human ; ABCA1 protein, mouse ; ABCG1 protein, human ; ABCG1 protein, mouse ; ATP Binding Cassette Transporter 1 ; ATP Binding Cassette Transporter, Sub-Family G, Member 1 ; Apolipoprotein A-I ; Apolipoproteins E ; Cholesterol, HDL ; Diterpenes ; Hypolipidemic Agents ; Liver X Receptors ; nagilactone C (24338-53-2)
Language	English
Publishing date	2016-07-26
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80340-6
ISSN	1755-3245 ; 0008-6363
ISSN (online)	1755-3245
ISSN	0008-6363
DOI	10.1093/cvr/cvw183
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 565: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito